中国医药：子公司天方药业达比加群酯胶囊获药品注册证书

Core Viewpoint - China Medical announced that its wholly-owned subsidiary, Tianfang Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for two drug registration certificates for Dabigatran Etexilate Capsules, a direct thrombin inhibitor used for various thromboembolic conditions [1] Group 1: Product Information - Dabigatran Etexilate is primarily used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, treat deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevent DVT and PE recurrence [1] - The drug was developed by Boehringer Ingelheim and was launched in Germany and the UK in March 2008, received FDA approval in October 2010, and was launched in China in February 2013 [1] Group 2: Market Context - As of the announcement date, besides Tianfang Pharmaceutical, 13 other companies, including Chengdu Baitai Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd., and Chengdu Yuandong Biopharmaceutical Co., Ltd., have obtained production licenses for this drug in China [1] - According to a third-party database, the sales revenue of this drug in China's three major terminal markets is projected to be approximately 571 million yuan in 2024, with an estimated 375 million yuan in the first three quarters of 2025 [1]